Agree Realty Celebrates BioDlink's Launch of World's First EGFR-Targeting ADC in China
- BioDlink launched MEIYOUHENG®, the world's first EGFR-targeting ADC, marking a milestone in biopharmaceuticals.
- The collaboration with Lepu Biopharma highlights BioDlink's efficiency and commitment to quality in biopharmaceutical production.
- This achievement enhances BioDlink's reputation and positions it as a key player in the global biopharmaceutical landscape.
Innovative Milestone in Biopharmaceuticals: BioDlink and Lepu Biopharma Launch Groundbreaking ADC
In a significant advancement for the biopharmaceutical industry, BioDlink, a leading biologics contract development and manufacturing organization (CDMO), has successfully launched MEIYOUHENG® (Becotatug Vedotin injection), the world's first EGFR-targeting antibody-drug conjugate (ADC). This landmark achievement, completed in partnership with Lepu Biopharma, marks the first ADC fully manufactured by a CDMO to enter the Chinese market. The collaboration between BioDlink and Lepu Biopharma illustrates the rapid evolution of China's biopharmaceutical ecosystem, which is increasingly showcasing its capacity for innovation and quality production.
The successful launch of MEIYOUHENG® is not only a testament to the technological prowess of BioDlink but also highlights the importance of efficient project execution in the biopharmaceutical sector. The partnership, which has been cultivated over two years, underscores BioDlink's robust capabilities in technology transfer and good manufacturing practices (GMP). Notably, the entire process from tech transfer to pivotal production is completed in under eleven months, with minimal deviations, demonstrating a commitment to quality and regulatory compliance. This level of efficiency and adherence to standards is crucial in a field where precision is paramount for both safety and efficacy.
The approval of MEIYOUHENG® by China's National Medical Products Administration (NMPA) on October 30, 2025, further solidifies the importance of this collaboration. Senior leaders from both BioDlink and Lepu Biopharma recently gathered at BioDlink's headquarters in Suzhou to celebrate this achievement, which is seen as a major step in advancing complex biologics. Dr. Jian Zhang, COO of BioDlink, expressed pride in the partnership, highlighting the significance of this breakthrough for the industry. Meanwhile, Dr. Ziye Sui, CEO of Lepu Biopharma, recognized BioDlink's role as a strategic partner throughout the development process, emphasizing the collaborative nature of their success.
In related developments, the successful launch of MEIYOUHENG® may set a precedent for future collaborations within the biopharmaceutical industry. As the market continues to evolve, the ability of CDMOs like BioDlink to facilitate groundbreaking innovations will be increasingly vital. This achievement not only enhances BioDlink's reputation but also positions it as a key player in the global biopharmaceutical landscape.
Related Cashu News

Lamar Advertising Co Moves to Value Indices Amid Shift in Investment Strategies
Lamar Advertising Co (Ticker: LAMR) has recently undergone a significant change in its market classification by being added to several Russell value and defensive indices. This inclusion reflects a sh…

Alexandria Real Estate Equities Advances Corporate Responsibility and Strengthens Its Position in Life Sciences
Alexandria Real Estate Equities (ARE) has made significant strides in enhancing its corporate responsibility efforts, as detailed in its recently published 2025 Corporate Responsibility Report. The re…

Healthpeak OP LLC Achieves Key Index Inclusion, Boosting Investor Interest and Trading Activity
Healthpeak OP LLC (Ticker: DOC) leverages significant market developments to reinforce its position in the real estate investment trust sector through strategic index inclusion, which may reshape inve…

Public Storage Boosts Financial Flexibility with New Credit Facility and Commercial Paper Program
Public Storage (Ticker: PSA) enhances its financial flexibility with a new unsecured credit facility and commercial paper program. Strategic Financial Innovations The company announces the closure of…

